{"id":125092,"date":"2026-07-01T11:33:00","date_gmt":"2026-07-01T17:33:00","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=125092"},"modified":"2026-07-01T11:33:00","modified_gmt":"2026-07-01T17:33:00","slug":"medicares-274-price-for-ozempic-and-wegovy-in-2027-will-you-pay-less","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/medicares-274-price-for-ozempic-and-wegovy-in-2027-will-you-pay-less\/","title":{"rendered":"Medicare’s $274 Price for Ozempic and Wegovy in 2027: Will You Pay Less?"},"content":{"rendered":"

If you’ve seen the headline that Medicare negotiated Ozempic and Wegovy down to $274 a month and assumed your costs are about to drop, here’s the honest answer: probably not, and possibly not at all, depending on who you are. That $274 figure is the price Medicare pays the drugmaker, not the price most patients pay at the pharmacy. It applies only to Medicare beneficiaries, it doesn’t touch commercial insurance, Medicaid, or cash-pay prices, and it isn’t even the only 2027 number in play. Let’s untangle what’s real, because there are three different figures floating around and they get mixed up constantly.<\/p>\n

Three numbers, one source of confusion<\/h3>\n

These three keep getting reported as if they’re the same thing. They aren’t.<\/p>\n

\n\n\n\n\n\n\n\n
The number<\/th>\nWhat it is<\/th>\nWho it helps<\/th>\n<\/tr>\n<\/thead>\n
$675\/month<\/td>\nNovo Nordisk’s voluntary list-price cut<\/td>\nCoinsurance and high-deductible patients<\/td>\n<\/tr>\n
$274\/month<\/td>\nIRA “maximum fair price” Medicare negotiated<\/td>\nWhat Medicare pays drugmakers, Part D only<\/td>\n<\/tr>\n
$245\/month<\/td>\nTrump administration “most-favored-nation” deal<\/td>\nAlso Medicare; may supersede the $274<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

The $274 comes from the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. CMS set a maximum fair price of $274 for a 30-day supply of semaglutide (Ozempic, Rybelsus, and Wegovy), roughly 71 percent off the near-$1,000 list price, effective January 1, 2027. Higher doses of Wegovy were set at $385.<\/p>\n

To complicate matters, the administration separately struck a voluntary most-favored-nation deal at $245, and CMS has signaled that for covered GLP-1 drugs the $245 price may end up superseding the $274. So even the “official” Medicare number has an asterisk.<\/p>\n

Why a lower negotiated price may not lower your bill<\/h3>\n

This is the part the headlines skip. A negotiated price is what Medicare reimburses the manufacturer. It is not a coupon, and it is not your copay. What you actually pay still depends on your Part D plan’s cost-sharing, your coverage phase, and, critically, whether your drug is even covered for your situation.<\/p>\n

Remember that Medicare Part D still cannot cover Ozempic or Wegovy for weight loss. The negotiated price attaches to the covered uses: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for cardiovascular risk reduction in people with established heart disease. If you’re a Medicare member who wants Wegovy purely to lose weight, the $274 price doesn’t open a door for you, because the door was never about price. It was about the indication.<\/p>\n

And if you don’t have Medicare at all? The drugmaker has been explicit that the maximum fair price applies only to Medicare beneficiaries and changes nothing for commercial insurance, Medicaid, or self-pay patients.<\/p>\n

Who actually benefits<\/h3>\n

The people who gain the most are Medicare members with a covered indication who pay coinsurance or sit in a high-deductible phase, since their share is calculated off a much lower underlying price. For them, 2027 could bring real relief.<\/p>\n

Consider a scenario where a Medicare member with type 2 diabetes pays a percentage of her drug’s cost during part of the year. When the underlying price her plan works from drops by roughly two-thirds, her share of that cost falls too. That’s a genuine win. But her neighbor, who wants Wegovy for weight loss and has no cardiovascular diagnosis, sees no change, because no negotiated price can cover a use that Part D excludes by statute.<\/p>\n

The clinical backdrop, briefly<\/h3>\n

It helps to remember why these drugs command attention and why governments bothered negotiating at all. Oral semaglutide alone has strong glycemic data behind it. In the PIONEER 2 trial, once-daily oral semaglutide produced significantly greater HbA1c reductions than empagliflozin in people with type 2 diabetes uncontrolled on metformin. Effective drugs at high list prices are exactly what price negotiation targets, but effectiveness and your out-of-pocket cost are two different conversations.<\/p>\n

If the headlines don’t help you, here’s what does<\/h3>\n

For a large group of people, especially those seeking a GLP-1 for weight loss without a qualifying medical indication, the 2027 Medicare numbers will be a non-event. A cash-pay telehealth path sidesteps the coverage question entirely, because it doesn’t run through Medicare or a formulary.<\/p>\n

That’s where a program like TrimRx fits. It connects you with licensed providers who prescribe semaglutide or tirzepatide when it’s clinically appropriate, and it bundles the provider visit and shipping into a flat monthly structure with no insurance required, with program pricing from $179 to $1,579 depending on the medication and plan. If you’d rather know your real number today than wait on a policy that may not apply to you, the free assessment quiz is a straightforward first step.<\/p>\n

This article is for general educational purposes and is not medical or financial advice. Drug pricing, negotiated rates, and coverage rules change frequently and vary by individual circumstance. Confirm current details with CMS, your plan, and a licensed provider before making decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

If you’ve seen the headline that Medicare negotiated Ozempic and Wegovy down to $274 a month and assumed your costs are about to drop,…<\/p>\n","protected":false},"author":7,"featured_media":62340,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[8],"tags":[],"class_list":["post-125092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ozempic"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/125092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=125092"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/125092\/revisions"}],"predecessor-version":[{"id":125093,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/125092\/revisions\/125093"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/62340"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=125092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=125092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=125092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}